PHD2 Constrains Antitumor CD8+ T-cell Activity

Cancer Immunol Res. 2023 Mar 1;11(3):339-350. doi: 10.1158/2326-6066.CIR-22-0099.

Abstract

The prolyl hydroxylase domain/hypoxia-inducible factor (PHD/HIF) pathway has been implicated in a wide range of immune and inflammatory processes, including in the oxygen-deprived tumor microenvironment. To examine the effect of HIF stabilization in antitumor immunity, we deleted Phd2 selectively in T lymphocytes using the cre/lox system. We show that the deletion of PHD2 in lymphocytes resulted in enhanced regression of EG7-OVA tumors, in a HIF-1α-dependent manner. The enhanced control of neoplastic growth correlated with increased polyfunctionality of CD8+ tumor-infiltrating lymphocytes, as indicated by enhanced expression of IFNγ, TNFα, and granzyme B. Phenotypic and transcriptomic analyses pointed to a key role of glycolysis in sustaining CTL activity in the tumor bed and identified the PHD2/HIF-1 pathway as a potential target for cancer immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD8-Positive T-Lymphocytes / metabolism
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / genetics
  • Hypoxia-Inducible Factor-Proline Dioxygenases*
  • Neoplasms*
  • Oxygen
  • Procollagen-Proline Dioxygenase / metabolism
  • Tumor Microenvironment

Substances

  • Hypoxia-Inducible Factor-Proline Dioxygenases
  • Procollagen-Proline Dioxygenase
  • Oxygen
  • Hypoxia-Inducible Factor 1, alpha Subunit